The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2017 | The LUME-BioNIS study and its aims
Keith Kerr, BSc, MB, ChB, FRCPath, FRCPE from the University of Aberdeen, Aberdeen, UK discusses the aims and results of the LUME-BioNIS study (NCT02671422). The LUME-BioNIS study investigated the presence of any biomarkers for response to angiogenic agents or inhibitors, specifically the small molecule inhibitor, nintedanib. Moreover, the study was carried out to identify a method that will allow physicians to recognize or detect patients that will benefit from this therapy. There are still no result available from this trial as data is currently being collected. This interview was recorded at the annual meeting of the European Lung Cancer Conference (ELCC) 2017, Geneva, Switzerland.
